Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Total Current Liabilities of $56.0 million in Q1 2026, up 21.83% quarter-over-quarter from $46.0 million in Q4 2025, and up 27.65% on a YoY basis from $43.9 million in Q1 2025.
Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $56.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.65% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (up 27.65% YoY), while the FY2025 annual figure was $46.0 million, down 8.95% from the prior year.
- Total Current Liabilities was $56.0 million for Q1 2026 at Oculis Holding AG, up from $46.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $56.0 million in Q1 2026 to a low of $12.5 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $33.8 million across 5 years, with a median of $32.0 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 183.23% in 2022, then fell 8.95% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $12.5 million in 2022, then surged by 72.47% to $21.5 million in 2023, then jumped by 134.65% to $50.5 million in 2024, then retreated by 8.95% to $46.0 million in 2025, then climbed by 21.83% to $56.0 million in 2026.
- The last three Total Current Liabilities figures came in at $56.0 million (Q1 2026), $46.0 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | 72.86 Mn |
| 10 | Oculis Holding AG | 8.45 Bn | 8.15 Bn | - | 56.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.01 Mn |
| Dec 31, 2025 | 45.98 Mn |
| Sep 30, 2025 | 42.16 Mn |
| Jun 30, 2025 | 44.14 Mn |
| Mar 31, 2025 | 43.88 Mn |
| Dec 31, 2024 | 50.50 Mn |
| Sep 30, 2024 | 31.99 Mn |
| Jun 30, 2024 | 26.13 Mn |
| Mar 31, 2024 | 20.80 Mn |
| Dec 31, 2023 | 21.52 Mn |
| Sep 30, 2023 | 25.08 Mn |
| Jun 30, 2023 | 18.69 Mn |
| Dec 31, 2022 | 12.48 Mn |
| Dec 31, 2021 | 4.41 Mn |